Karuna Therapeutics Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 210

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $13.8B

Karuna Therapeutics General Information

Description

Developer of a drug discovery platform intended to create and deliver transformative medicines for people living with psychiatric and neurological conditions. The company offers drug development capabilities for neurological and neuropsychiatric diseases, enabling the development of novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs.

Contact Information

Formerly Known As
Karuna Pharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 99 High Street
  • Floor 26
  • Boston, MA 02110
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 99 High Street
  • Floor 26
  • Boston, MA 02110
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Karuna Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 18-Mar-2024 $13.8B Completed Generating Revenue
9. 2PO 24-Mar-2023 Completed Generating Revenue
8. 2PO 11-Aug-2022 Completed Generating Revenue
7. Secondary Transaction - Open Market 26-Aug-2020 Completed Clinical Trials - Phase 2
6. IPO 28-Jun-2019 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 01-Apr-2019 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A) 02-Aug-2018 Completed Clinical Trials - Phase 1
3. Grant 19-Jun-2018 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 25-May-2011 $244K $244K Completed Startup
1. Accelerator/Incubator 25-May-2011 Completed Startup
To view Karuna Therapeutics’s complete valuation and funding history, request access »

Karuna Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Seed 4,412,500 $0.000100 $1 $1 1x $1 27.84%
To view Karuna Therapeutics’s complete cap table history, request access »

Karuna Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform intended to create and deliver transformative medicines for people living with ps
Drug Discovery
Boston, MA
210 As of 2022

Broomfield, CO
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Karuna Therapeutics Competitors (49)

One of Karuna Therapeutics’s 49 competitors is Cerecin, a Venture Capital-Backed company based in Broomfield, CO.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cerecin Venture Capital-Backed Broomfield, CO
Verge Labs Venture Capital-Backed San Francisco, CA
MycoMedica Life Sciences Venture Capital-Backed Shelton, WA
Alzheon Venture Capital-Backed Framingham, MA
Praxis (Drug Discovery) Formerly VC-backed Boston, MA
You’re viewing 5 of 49 competitors. Get the full list »

Karuna Therapeutics Patents

Karuna Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026072610-A1 Process for preparing 3-(4-(hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine l-(+)-tartrate Pending 25-Sep-2024
WO-2026072607-A1 Process for preparing 3-chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole Pending 25-Sep-2024
WO-2026064593-A1 Method and compositions relating to the treatment of neuro-degenerative and psychiatric diseases Pending 20-Sep-2024
WO-2025255488-A2 Xanomeline quercetin complexes and trospium salts Pending 06-Jun-2024
WO-2025255488-A3 Xanomeline quercetin complexes and trospium salts Pending 06-Jun-2024 C07D417/04
To view Karuna Therapeutics’s complete patent history, request access »

Karuna Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Karuna Therapeutics Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARCH Venture Partners Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
CONNECT (San Diego) Accelerator/Incubator Minority
Eventide Asset Management Venture Capital Minority
Fidelity Management & Research Company Asset Manager Minority
You’re viewing 5 of 13 investors. Get the full list »

Karuna Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

18.45 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Karuna Therapeutics’s complete esg history, request access »

Karuna Therapeutics FAQs

  • When was Karuna Therapeutics founded?

    Karuna Therapeutics was founded in 2009.

  • Where is Karuna Therapeutics headquartered?

    Karuna Therapeutics is headquartered in Boston, MA.

  • What is the size of Karuna Therapeutics?

    Karuna Therapeutics has 210 total employees.

  • What industry is Karuna Therapeutics in?

    Karuna Therapeutics’s primary industry is Drug Discovery.

  • Is Karuna Therapeutics a private or public company?

    Karuna Therapeutics is a Private company.

  • What is the current valuation of Karuna Therapeutics?

    The current valuation of Karuna Therapeutics is .

  • What is Karuna Therapeutics’s current revenue?

    The current revenue for Karuna Therapeutics is .

  • How much funding has Karuna Therapeutics raised over time?

    Karuna Therapeutics has raised $975M.

  • Who are Karuna Therapeutics’s investors?

    ARCH Venture Partners, Alexandria Venture Investments, CONNECT (San Diego), Eventide Asset Management, and Fidelity Management & Research Company are 5 of 13 investors who have invested in Karuna Therapeutics.

  • Who are Karuna Therapeutics’s competitors?

    Cerecin, Verge Labs, MycoMedica Life Sciences, Alzheon, and Praxis (Drug Discovery) are some of the 49 competitors of Karuna Therapeutics.

  • When was Karuna Therapeutics acquired?

    Karuna Therapeutics was acquired on 18-Mar-2024.

  • Who acquired Karuna Therapeutics?

    Karuna Therapeutics was acquired by Bristol-Myers Squibb.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process